Cargando…

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoff, Nicole A., Bratcher, Anna, Kelly, J. Daniel, Musene, Kamy, Kompany, Jean Paul, Kabamba, Michel, Mbala-Kingebeni, Placide, Dighero-Kemp, Bonnie, Kocher, Gregory, Elliott, Elizabeth, Reilly, Cavan, Halbrook, Megan, Ilunga Kebela, Benoit, Gadoth, Adva, Ngoie Mwamba, Guillaume, Tambu, Merly, McIlwain, David R., Mukadi, Patrick, Hensley, Lisa E., Ahuka-Mundeke, Steve, Rutherford, George W., Muyembe-Tamfum, Jean Jacques, Rimoin, Anne W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833182/ https://www.ncbi.nlm.nih.gov/pubmed/35110410 http://dx.doi.org/10.1073/pnas.2118895119

Ejemplares similares

Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo
por: Hoff, Nicole A., et al.
Publicado: (2021)

Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo
por: Bratcher, Anna, et al.
Publicado: (2021)

Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo
por: Shaffer, Kelly C. L., et al.
Publicado: (2022)

Correction: Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo
por: Bratcher, Anna, et al.
Publicado: (2022)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo
por: Barrall, Angelica L., et al.
Publicado: (2022)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

The rapidly evolving monkeypox epidemic: A call to action to leave no one behind
por: Strathdee, Steffanie A., et al.
Publicado: (2022)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines
por: Coller, Beth-Ann G., et al.
Publicado: (2022)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Changes in childhood vaccination coverage over time in the Democratic Republic of the Congo
por: Alfonso, Vivian H., et al.
Publicado: (2019)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
por: Schwartz, David A.
Publicado: (2020)

Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions
por: Mbala-Kingebeni, Placide, et al.
Publicado: (2019)

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
por: Boum, Yap, et al.
Publicado: (2020)

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
por: Halperin, Scott A, et al.
Publicado: (2019)

Monkeypox and Global Health Inequities: A Tale as Old as Time…
por: Malta, Monica, et al.
Publicado: (2022)

Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey
por: Alfonso, Vivian H., et al.
Publicado: (2022)

Risk Factors for Ebola Exposure in Health Care Workers in Boende, Tshuapa Province, Democratic Republic of the Congo
por: Doshi, Reena H, et al.
Publicado: (2020)

Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of Congo—Priorities for Achieving Control
por: Nachega, Jean B., et al.
Publicado: (2020)

Neurological, Cognitive, and Psychological Findings Among Survivors of Ebola Virus Disease From the 1995 Ebola Outbreak in Kikwit, Democratic Republic of Congo: A Cross-sectional Study
por: Kelly, J Daniel, et al.
Publicado: (2019)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
por: Monath, Thomas P., et al.
Publicado: (2019)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

Investigating the Circulation of Ebola Viruses in Bats during the Ebola Virus Disease Outbreaks in the Equateur and North Kivu Provinces of the Democratic Republic of Congo from 2018
por: Lacroix, Audrey, et al.
Publicado: (2021)

Cost-effectiveness of incorporating Ebola prediction score tools and rapid diagnostic tests into a screening algorithm: A decision analytic model
por: Tshomba, Antoine Oloma, et al.
Publicado: (2023)

Revue d’épidémies de grippe humaine avant la mise en place de la surveillance sentinelle en République Démocratique du Congo
por: Nkwembe-Ngabana, Edith, et al.
Publicado: (2017)

Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak
por: Tshomba, Antoine Oloma, et al.
Publicado: (2022)

Challenges in interpreting SARS-CoV-2 serological results in African countries
por: Nkuba Ndaye, Antoine, et al.
Publicado: (2021)

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2
por: Mariën, Joachim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f7rhvu2vedi9anudfs2e0bkl9b